2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 697

Venous and Arterial Thrombosis in SLE: Differences in Natural History
Abstract Number: 1772

Venous Thromboembolic Events in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Abstract Number: 2255

Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study
Abstract Number: 394

Very Low or High Body Mass Index Negatively Affects patients’ Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort
Abstract Number: 52

Visceral Fat Measured By Dual-Energy X-Ray Absorptiometry Is Associated with Increased Risk of Non-Spine Fractures in Nonobese Elderly Women: a Population-Based Prospective Cohort Analysis from the São Paulo Ageing & Health (SPAH) Study
Abstract Number: 2636

Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE)
Abstract Number: 2559

Vitamin D insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders
Abstract Number: 1923

Vitamin D Restores Lupus Myeloid Angiogenic Cell Function Via Down-Regulation of IP-10/CXCL-10
Abstract Number: 1391

Weight Loss and Risk of Death in Rheumatoid Arthritis
Abstract Number: 1385

What Discriminates Best Flares in Rheumatoid Arthritis (RA)? a Subanalysis of the Strass Treatment Tapering in RA Study
Abstract Number: 2011

What Do State Legislators Think about Arthritis? Results of Focus Groups with State Legislators
Abstract Number: 58

What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis
Abstract Number: 2132

What Is Associated with X- Ray Progression at 5 Years in Rheumatoid Arthritis (RA) Patients in Low Disease Activity?
Abstract Number: 382

What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Abstract Number: 583

What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].